ACW XanaMIA Alzheimers open label trial commences
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Actinogen Medical Limited has announced the commencement of the open-label extension phase of the XanaMIA trial for Alzheimer's disease, allowing participants to receive active treatment for an extended period. The randomized phase of the trial continues alongside this extension, with final results expected in the future. The announcement highlights the potential of Xanamem as a significant therapy for Alzheimer's patients, emphasizing its safety profile compared to other treatments.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- ACW successfully completes $16.8m Placement and SPP
- ACW HY26 results - XanaMIA pivotal Alzheimers trial progress
- Actinogen HY2025 financial report and Appendix 4D
- ACW receives further $1.9m FY2025 R&D rebate from ATO
- Actinogen receives positive Interim Analysis recommendation from its independent Data Monitoring Committee to continue the XanaMIA pivotal Alzheimer’s disease trial
Later from Actinogen Medical
- Actinogen commences open-label phase of XanaMIA Alzheimer’s trial and provides business update
- Correction-March2026 quarterly activity report & Appendix 4C
- Actinogen receives positive scientific advice from EMA
- Actinogen receives positive EMA scientific advice aligned with prior FDA guidance for its Alzheimer’s disease program
- ACW third positive XanaMIA trial data committee review
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical